Kite’s CAR-T Therapy Makes It Back Onto EMA’s PRIME, Along With Three New Products
Executive Summary
The four latest products to be accepted onto the European Medicines Agency’s popular priority medicines scheme target mantle cell lymphoma, chikungunya, hematopoietic stem cell transplant patients, and the rare monogenic disease, X-linked myotubular myopathy.
You may also be interested in...
Yet Another Myeloma CAR-T Therapy Makes It Onto EMA’s PRIME
Only two of seven applications for entry into the European Medicines Agency’s priority medicines scheme for getting treatments for unmet medical need to patients faster were successful last month.
EU CAR-T Race Tightens After Yescarta Reverts To Standard Review
Kite and Novartis are vying to be the first company to have a CAR-T therapy approved in the EU. Both companies are hoping to be able to treat patients with r/r DLBCL.
Bharat Enters Chikungunya Fray As Vaccine Moves Into Trials
Indian vaccine developer Bharat Biotech has moved a candidate vaccine for chikungunya into Phase I trials, joining over a dozen firms worldwide hoping to commercialize the first vaccine to halt transmission of the painful mosquito-borne illness, which is spreading globally.